[go: up one dir, main page]

FR2802423B1 - Compositions pharmaceutiques - Google Patents

Compositions pharmaceutiques

Info

Publication number
FR2802423B1
FR2802423B1 FR0016220A FR0016220A FR2802423B1 FR 2802423 B1 FR2802423 B1 FR 2802423B1 FR 0016220 A FR0016220 A FR 0016220A FR 0016220 A FR0016220 A FR 0016220A FR 2802423 B1 FR2802423 B1 FR 2802423B1
Authority
FR
France
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0016220A
Other languages
English (en)
Other versions
FR2802423A1 (fr
Inventor
Juergen Sigg
Michael Billington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10866648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2802423(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of FR2802423A1 publication Critical patent/FR2802423A1/fr
Application granted granted Critical
Publication of FR2802423B1 publication Critical patent/FR2802423B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0016220A 1999-12-20 2000-12-13 Compositions pharmaceutiques Expired - Lifetime FR2802423B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9930058.4A GB9930058D0 (en) 1999-12-20 1999-12-20 Organic compounds

Publications (2)

Publication Number Publication Date
FR2802423A1 FR2802423A1 (fr) 2001-06-22
FR2802423B1 true FR2802423B1 (fr) 2005-03-25

Family

ID=10866648

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0016220A Expired - Lifetime FR2802423B1 (fr) 1999-12-20 2000-12-13 Compositions pharmaceutiques

Country Status (33)

Country Link
US (1) US8119148B2 (fr)
EP (2) EP1437127A1 (fr)
JP (2) JP4588281B2 (fr)
KR (2) KR20040098034A (fr)
CN (1) CN1216594C (fr)
AR (1) AR030175A1 (fr)
AT (1) ATE269694T1 (fr)
AU (1) AU777619B2 (fr)
BE (2) BE1013706A5 (fr)
BR (1) BR0016524A (fr)
CA (1) CA2390029C (fr)
CO (1) CO5261608A1 (fr)
CZ (1) CZ302737B6 (fr)
DE (1) DE60011809T2 (fr)
DK (1) DK1239832T3 (fr)
ES (1) ES2223641T3 (fr)
FR (1) FR2802423B1 (fr)
GB (1) GB9930058D0 (fr)
HU (1) HU226486B1 (fr)
IL (2) IL149498A0 (fr)
IT (1) ITMI20002717A1 (fr)
MX (1) MXPA02006142A (fr)
MY (1) MY126868A (fr)
NO (1) NO331990B1 (fr)
NZ (1) NZ518755A (fr)
PE (1) PE20010933A1 (fr)
PL (1) PL201331B1 (fr)
PT (1) PT1239832E (fr)
RU (1) RU2277912C2 (fr)
SK (1) SK287553B6 (fr)
TR (2) TR200402419T4 (fr)
WO (1) WO2001045671A2 (fr)
ZA (1) ZA200204863B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
DE10224086A1 (de) * 2002-05-31 2003-12-11 Bayer Ag Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker
NZ538859A (en) 2002-09-20 2006-12-22 Fmc Corp Cosmetic sunscreen composition containing microcrystalline cellulose
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
BRPI0414112A (pt) 2003-09-03 2006-10-31 Novartis Ag uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2007007182A2 (fr) * 2005-07-08 2007-01-18 Aurobindo Pharma Limited Formes galeniques solides d'agent antiepileptique
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
ES2396051T3 (es) * 2006-04-26 2013-02-18 Supernus Pharmaceuticals, Inc. Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
KR20080076667A (ko) * 2007-02-15 2008-08-20 주식회사 중외제약 요변성 약학 조성물
AR078283A1 (es) * 2009-09-10 2011-10-26 Bial Portela & Ca Sa Formulaciones de suspension oral de dibenzazepina carboxamidas
CN104288104A (zh) * 2014-09-24 2015-01-21 万特制药(海南)有限公司 奥卡西平干混悬剂及其制备方法
AU2016381366A1 (en) 2015-12-30 2018-06-28 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
CN109010322A (zh) * 2018-07-13 2018-12-18 山东达因海洋生物制药股份有限公司 一种包含奥卡西平的口腔分散膜剂及其制备方法
CN115487145B (zh) * 2022-10-10 2023-09-01 上海奥科达医药科技股份有限公司 一种奥卡西平口服混悬液及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH500196A (de) 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
US4004029A (en) * 1974-05-13 1977-01-18 The Upjohn Company Compositions and method for treating epilepsy and convulsions
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
RO81639A2 (fr) * 1981-02-27 1983-06-01 Intreprinderea De Medicamente "Biofarm",Ro Procede d'obtention d'un poudre suspendable orale d'ampiciline
CH649080A5 (de) 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
US4427681A (en) 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
JPS60204713A (ja) 1984-03-30 1985-10-16 Zenyaku Kogyo Kk 水性懸濁組成物
US4693901A (en) 1985-12-10 1987-09-15 Cardinal Biological, Ltd. Shelf stable dairylike products
GB8618847D0 (en) 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
IL86211A (en) * 1987-05-04 1992-03-29 Ciba Geigy Ag Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation
IL90245A (en) 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorbate comprising ranitidine together with a synthetic cation exchange resin, its preparation and pharmaceutical compositions containing it
ES2054089T3 (es) 1988-11-10 1994-08-01 Ciba Geigy Ag Formulaciones orales liquidas.
GB9102579D0 (en) 1991-01-24 1991-03-27 Glaxo Group Ltd Compositions
US5272137A (en) 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
GB9219524D0 (en) * 1992-09-15 1992-10-28 Smithkline Beecham Plc Novel composition
FR2699077B1 (fr) 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
WO1994016693A1 (fr) * 1993-01-19 1994-08-04 Warner-Lambert Company Formulation ci-981, orale, stable et son procede de preparation
FR2702148B1 (fr) 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2702149B1 (fr) 1993-06-03 1995-04-07 Rhone Poulenc Rorer Sa Application de la lamotrigine dans le traitement du neuro-sida.
FR2702151B1 (fr) 1993-06-03 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
DE4423078B4 (de) * 1994-07-01 2005-01-13 Awd.Pharma Gmbh & Co. Kg Verfahren zur Herstellung einer Carbamazepin-Arzneiform mit verzögerter Wirkstofffreisetzung
EP0785783A1 (fr) 1994-10-14 1997-07-30 Janssen Pharmaceutica N.V. Suspensions de sabeluzole administrees par voie orale
DE4443966A1 (de) * 1994-12-09 1996-06-13 Basf Ag Thermoplastische Formmassen
PT101732B (pt) 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
IT1277663B1 (it) 1995-09-28 1997-11-11 Crinos Industria Farmaco Sospensioni acquose stabili di mesalazina per uso topico
PT101876B (pt) * 1996-05-27 1999-09-30 Portela & Ca Sa Novos derivados de 10,11-di-hidro-10-oxo-5h-dibenzo(b,f)azepina-5-carboxamida
IT1286496B1 (it) 1996-11-20 1998-07-15 Leetrim Ltd Dublin Composizione farmaceutica orale ad attivita' antipiretica,analgesica ed antiinfiammatoria
US6037380A (en) * 1997-04-11 2000-03-14 Fmc Corporation Ultra-fine microcrystalline cellulose compositions and process
US6146876A (en) * 1999-06-11 2000-11-14 Millennium Pharmaceuticals, Inc. 22025, a novel human cyclic nucleotide phosphodiesterase
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CN1216594C (zh) 2005-08-31
FR2802423A1 (fr) 2001-06-22
KR100496368B1 (ko) 2005-06-21
DK1239832T3 (da) 2004-08-09
PE20010933A1 (es) 2001-09-17
JP4588281B2 (ja) 2010-11-24
EP1239832A2 (fr) 2002-09-18
WO2001045671A2 (fr) 2001-06-28
HU226486B1 (en) 2009-03-02
CO5261608A1 (es) 2003-03-31
NO20022849D0 (no) 2002-06-14
RU2277912C2 (ru) 2006-06-20
ES2223641T3 (es) 2005-03-01
NZ518755A (en) 2004-04-30
CA2390029A1 (fr) 2001-06-28
GB9930058D0 (en) 2000-02-09
US20030004155A1 (en) 2003-01-02
SK8652002A3 (en) 2002-12-03
DE60011809T2 (de) 2005-06-30
JP2003518036A (ja) 2003-06-03
MY126868A (en) 2006-10-31
CZ302737B6 (cs) 2011-10-12
ZA200204863B (en) 2003-03-17
HUP0203782A2 (hu) 2003-03-28
PT1239832E (pt) 2004-10-29
PL201331B1 (pl) 2009-03-31
KR20020062658A (ko) 2002-07-26
WO2001045671A3 (fr) 2002-02-21
AU777619B2 (en) 2004-10-21
ITMI20002717A1 (it) 2002-06-15
NO331990B1 (no) 2012-05-21
JP2006312651A (ja) 2006-11-16
HUP0203782A3 (en) 2005-01-28
HK1050474A1 (en) 2003-06-27
US8119148B2 (en) 2012-02-21
IL149498A0 (en) 2002-11-10
MXPA02006142A (es) 2002-12-05
ATE269694T1 (de) 2004-07-15
NO20022849L (no) 2002-06-14
AU2511801A (en) 2001-07-03
RU2002119210A (ru) 2004-02-27
KR20040098034A (ko) 2004-11-18
CZ20022138A3 (cs) 2002-09-11
SK287553B6 (sk) 2011-01-04
PL355535A1 (en) 2004-05-04
TR200201459T2 (tr) 2002-09-23
EP1239832B1 (fr) 2004-06-23
EP1437127A1 (fr) 2004-07-14
BR0016524A (pt) 2002-09-24
AR030175A1 (es) 2003-08-13
CN1411367A (zh) 2003-04-16
CA2390029C (fr) 2010-01-26
TR200402419T4 (tr) 2004-12-21
DE60011809D1 (en) 2004-07-29
BE1013706A5 (fr) 2002-06-04
IL149498A (en) 2011-05-31
BE1014502A5 (fr) 2003-11-04

Similar Documents

Publication Publication Date Title
PT1242087E (pt) Composicoes farmaceuticas
NO20015175D0 (no) Farmasöytisk sammensetning
FR2795324B1 (fr) Compositions pharmaceutiques stabilisees
FI991485L (fi) Uusi farmaseuttinen koostumus
FR2775596B1 (fr) Nouvelles compositions pharmaceutiques
IS5046A (is) Lyfjasamsetningar
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
ITMI20010748A0 (it) Composizioni farmaceutiche
DK1524266T3 (da) Farmaceutisk sammensætning
NO20015670L (no) Forbedrede farmasöytiske formuleringer
NO20022606D0 (no) Farmasöytiske kombinasjoner
NO20026123L (no) Farmasöytiske sammensetninger
FR2802423B1 (fr) Compositions pharmaceutiques
NO20014926L (no) Farmasöytiske forbindelser
NO20031095D0 (no) Farmasöytiske sammensetninger
DK1227817T3 (da) Ciclesonid-holdigt vandigt farmaceutisk præparat
FI4488U1 (fi) Farmaseuttinen koostumus
FR2779145B1 (fr) Nouvelles compositions pharmaceutiques
AR025867A1 (es) Formulacion portasdora farmaceutica
FR2797444B1 (fr) Compositions pharmaceutiques comprenant des 4-quinolones
MA26604A1 (fr) Compositions pharmaceutiques.
NO20004816D0 (no) Ny farmasøytisk formulering
EE200200689A (et) Ravimkoostised
SE9901967D0 (sv) New solid dosage formulation

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 20